CompletedPhase 2
A Biomarker Study of ATH434 in Participants With MSA
Key facts
- Who runs it
- Alterity Therapeutics
- Where
- Nashville, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 10 people enrolled
- Started
- 23 May 2023
- Ended
- 26 Feb 2025
- Type of study
- Interventional
- Treatments tested
- ATH434
- Record updated
- 1 April 2025
Who can take part
- Age
- 30 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participant has clinical features of parkinsonism
- Participant has evidence of orthostatic hypotension and/or bladder dysfunction
- Participant has ataxia and/or pyramidal signs on neurological examination
- Participant has biomarker evidence of MSA in biologic fluid and on MRI
Who cannot take part
- Participant is unable to swallow study drug
- Participant has any significant neurological disorder other than MSA
- Participant has an unstable medical or psychiatric illness
- Participant is unable to attend study visits or complete study procedures
- Participant has structural brain abnormality on MRI
- Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesNo longer taking part
About the trial
What the trial wants to find out
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
The group in the trial
- ATH434Treatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy
- Record updated
- 1 April 2025